ZETIA (ezetimibe)

The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.

I AM A HEALTHCARE PROFESSIONAL I AM NOT A HEALTHCARE PROFESSIONAL
 
Important Information About ZETIA
This requires Flash to play. Click here to download.
Click here for Study Design
bullet gif The effect of ZETIA on cardiovascular morbidity and mortality has not been determined.
bullet gif ZETIA, administered alone or in combination with an HMG-CoA reductase inhibitor (statin), is indicated as adjunctive therapy to diet for the reduction of elevated TOTAL-C, LDL-C, and Apo B in patients with primary (heterozygous familial and nonfamilial) hyperlipidemia when diet alone is not enough.
SELECTED CAUTIONARY INFORMATION
bullet gif ZETIA is not recommended in patients with moderate to severe hepatic impairment.
bullet gif The coadministration of ZETIA with fibrates other than fenofibrate is not recommended until use in patients is adequately studied.
bullet gif Exercise caution when using ZETIA and cyclosporine concomitantly because exposure to both drugs is increased. Cyclosporine concentrations should be monitored in these patients.
bullet gif ZETIA should be used in pregnant or nursing women only if the benefit outweighs the risk.
bullet gif In clinical trials, regardless of causality assessment, the most frequent side effects for ZETIA coadministered with a statin vs statin alone included nasopharyngitis (3.7% vs 3.3%), myalgia (3.2% vs 2.7%), upper respiratory tract infection (2.9% vs 2.8%), arthralgia (2.6% vs 2.4%), and diarrhea (2.5% vs 2.2%); for ZETIA administered alone vs placebo: upper respiratory tract infection (4.3% vs 2.5%), diarrhea (4.1% vs 3.7%), arthralgia (3.0% vs 2.2%), sinusitis (2.8% vs 2.2%), pain in extremity (2.7% vs 2.5%), and fatigue (2.4% vs 1.5%).

Before prescribing ZETIA, please read the Prescribing Information.

a

Study Design1: A 6-week, randomized, double-blind study (N=184) comparing LDL-C reduction with adding ZETIA to a stable dose of atorvastatin 20 mg vs titrating atorvastatin from 20 mg to 40 mg in patients with hypercholesterolemia at moderately high risk for CHD. Mean treated baseline LDL-C for ZETIA added to atorvastatin 20 mg was 120 mg/dL and for atorvastatin 40 mg alone was 118 mg/dL. Patients had a 31% additional mean reduction in LDL-C with adding ZETIA to atorvastatin 20 mg and an 11% additional mean reduction in LDL-C from baseline with titrating atorvastatin 20 mg to 40 mg.
 

Reference:
1. Conard SE, Bays HE, Leiter LA, et al.  Efficacy and safety of ezetimibe added on to atorvastatin (20 mg) versus uptitration of atorvastatin (to 40 mg) in hypercholesterolemic patients at moderately high risk for coronary heart disease. Am J Cardiol. 2008;102:1489–1494.

This site is intended only for health care professionals of the United States, its territories, and Puerto Rico.

For non-US health care professionals, click here.

ZETIA and VYTORIN are registered trademarks of MSP Singapore Company, LLC.

Merck/Schering-Plough Pharmaceuticals        Merck/Schering-Plough Pharmaceuticals        Merck/Schering-Plough Pharmaceuticals
MerckMedicus™, MerckSource®, and MerckServices® are trademarks of Merck & Co., Inc.

Back to Top

21050228(1)-06/10-ZET